[Tenofovir alafenamide in patients with HIV diagnosis]

Salvi R, Soto N, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A.
Record ID 32018001512
Spanish
Original Title: Tenofovir alafenamida en pacientes con diagnóstico de VIH
Authors' recomendations: CONCLUSIONS High-quality evidence shows that boosted tenofovir alafenamide (TAF) shows a similar rate of viral suppression and genotypic resistance to those of tenofovir disoproxil fumarate (TDF), with a tendency to a better safety profile at bone mineral density level and kidney function in treatment naïve patients with HIV diagnosis. There is consensus among the main clinical practice guidelines and sponsors on recommending the use of TAF-containing schemes in patients with a creatinine clearance above 30 mL/min, with no prior treatment in combination with other agents, whenever the cost is not higher than other commonly used antiretroviral drug treatments. Unlike TAF, TDF should be used in patients with a creatinine clearance over 50-60 mL/min. No cost-effectiveness or budget impact studies were found for Latin America. The price of Genvoya© (elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide) in Argentina is lower than Stribild© (elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate). These formulations allow a simplified treatment scheme, which results in better treatment compliance.
Details
Project Status: Completed
Year Published: 2018
URL for published report: https://www.iecs.org.ar/home-ets/
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Argentina
MeSH Terms
  • HIV Infections
  • Anti-HIV Agents
  • Tenofovir
Contact
Organisation Name: Institute for Clinical Effectiveness and Health Policy
Contact Address: Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name: info@iecs.org.ar
Contact Email: info@iecs.org.ar
Copyright: Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.